Current Report Filing (8-k)
February 27 2017 - 6:09AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): February 27, 2017 (February 23, 2017)
______________________________
Neuralstem, Inc.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
000-1357459
|
|
52-2007292
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File No.)
|
|
(IRS Employee Identification No.)
|
20271 Goldenrod Lane, 2
nd
Floor, Germantown, Maryland 20876
(Address of Principal Executive Offices)
(301) 366-4960
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On February 23, 2017, representatives of
Neuralstem, Inc. (the “Company”) presented a corporate and clinical overview presentation to investors. A copy of the
presentation is attached to this report as Exhibit 99.01.
The information contained in this Item
7.01 to this Current Report on Form 8-K and the exhibit attached hereto pertaining to this item shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing. The information set forth in the exhibits to this Form 8-K relating to this item 7.01 shall not be deemed an
admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements
of Regulation FD.
Item 9.01 Financial
Statement and Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.01
|
|
Presentation Presented on February 23, 2017
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: February 27, 2017
|
Neuralstem, Inc.
|
|
|
|
|
|
|
|
|
/s/ Richard Daly
|
|
|
By: Richard Daly
|
|
|
Chief Executive Officer
|
|
INDEX OF EXHIBITS
Exhibit
No.
|
|
Description
|
|
|
99.01
|
|
Presentation Presented on February 23, 2017
|
|
|
|
|
|
|
|
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024